Questions have been raised over Bourla’s cozy relationship with EU Commission President Ursula von der Leyen during the multi-billion dollar deal negotiations.
Pfizer CEO Albert Bourla was scheduled to appear before the COVID panel of the EU Parliament on 10 October to face some tough questioning over the sale of mRNA vaccines for COVID to the EU.
The secretive deals were struck in direct communications between Bourla and von der Leyen when they should have gone through an independent EU vaccine procurement committee.
DTNZ reported in July how von der Leyen claimed she ‘couldn’t find’ the texts between her and Bourla. It has since emerged that the Commission has also refused to provide the watchdog committee with any minutes, or other documents relating to the negotiations, which saw Pfizer supply 1.8 billion doses of its ineffective and unsafe mRNA medication.
A spokesperson for Pfizer told Politico that the company’s president of international development markets, Janine Small, would attend the committee hearing. ‘She has been identified as best placed to support the committee in meeting their objectives,’ the spokesperson said.